http://www.theflyonthewall.com/permalinks/entry.php/MNKDid1851165/MNKD-MannKind-price-target-raised-to--from--at-Piper-Jaffray
MannKind price target raised to $8.40 from $6 at Piper Jaffray
Piper Jaffray raised its price target for MannKind shares ahead of the data from the AFFINITY Phase III trials in mid-August. Piper expects positive data to support FDA approval and sees significant upside potential for the stock from a licensing agreement or acquisition. The firm keeps an Overweight rating on MannKind with an increased price target of $8.40.
